UBS Group’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.26M | Sell |
9,400
-2,500
| -21% | -$1.91M | ﹤0.01% | 3682 |
|
|
2025
Q4 | $9.19M | Sell |
11,900
-4,600
| -28% | -$3.12M | ﹤0.01% | 3376 |
|
|
2025
Q3 | $9.28M | Sell |
16,500
-4,500
| -21% | -$2.54M | ﹤0.01% | 3379 |
|
|
2025
Q2 | $11M | Sell |
21,000
-9,400
| -31% | -$5.25M | ﹤0.01% | 2983 |
|
|
2025
Q1 | $19.3M | Sell |
30,400
-43,100
| -59% | -$29.6M | ﹤0.01% | 2362 |
|
|
2024
Q4 | $52.4M | Buy |
73,500
+2,000
| +3% | +$1.68M | 0.01% | 1426 |
|
|
2024
Q3 | $75.2M | Buy |
71,500
+2,400
| +3% | +$2.67M | 0.02% | 896 |
|
|
2024
Q2 | $72.6M | Sell |
69,100
-12,700
| -16% | -$12.3M | 0.02% | 812 |
|
|
2024
Q1 | $78.7M | Sell |
81,800
-28,500
| -26% | -$27.1M | 0.02% | 772 |
|
|
2023
Q4 | $96.9M | Buy |
110,300
+4,100
| +4% | +$3.38M | 0.03% | 583 |
|
|
2023
Q3 | $87.4M | Buy |
106,200
+28,400
| +37% | +$22.3M | 0.03% | 552 |
|
|
2023
Q2 | $55.9M | Buy |
77,800
+2,700
| +4% | +$2.08M | 0.02% | 770 |
|
|
2023
Q1 | $61.7M | Sell |
75,100
-48,700
| -39% | -$36.7M | 0.02% | 674 |
|
|
2022
Q4 | $89.3M | Buy |
123,800
+3,100
| +3% | +$2.29M | 0.03% | 533 |
|
|
2022
Q3 | $83.1M | Buy |
120,700
+6,500
| +6% | +$4.09M | 0.04% | 493 |
|
|
2022
Q2 | $67.5M | Buy |
114,200
+9,800
| +9% | +$6.37M | 0.03% | 589 |
|
|
2022
Q1 | $72.9M | Buy |
104,400
+44,000
| +73% | +$27.8M | 0.02% | 654 |
|
|
2021
Q4 | $38.1M | Buy |
60,400
+13,845
| +30% | +$8.51M | 0.01% | 1125 |
|
|
2021
Q3 | $28.2M | Buy |
46,555
+5,300
| +13% | +$3.29M | 0.01% | 1233 |
|
|
2021
Q2 | $23M | Buy |
41,255
+3,200
| +8% | +$1.62M | 0.01% | 1385 |
|
|
2021
Q1 | $18M | Buy |
+38,055
| New | +$18.5M | 0.01% | 1518 |
|
|
2020
Q2 | – | Sell |
-50
| Closed | -$24K | – | 8282 |
|
|
2020
Q1 | $24K | Sell |
50
-350
| -88% | -$144K | ﹤0.01% | 6380 |
|
|
2019
Q4 | $150K | Buy |
400
+350
| +700% | +$118K | ﹤0.01% | 5781 |
|
|
2019
Q3 | $14K | Hold |
50
| – | – | ﹤0.01% | 6955 |
|
|
2019
Q2 | $16K | Hold |
50
| – | – | ﹤0.01% | 6775 |
|
|
2019
Q1 | $21K | Sell |
50
-520
| -91% | -$214K | ﹤0.01% | 6278 |
|
|
2018
Q4 | $213K | Sell |
570
-10,650
| -95% | -$3.9M | ﹤0.01% | 4916 |
|
|
2018
Q3 | $4.53M | Buy |
11,220
+10,174
| +973% | +$3.87M | ﹤0.01% | 2439 |
|
|
2018
Q2 | $361K | Sell |
1,046
-6,504
| -86% | -$2.03M | ﹤0.01% | 4559 |
|
|
2018
Q1 | $2.6M | Buy |
+7,550
| New | +$2.63M | ﹤0.01% | 2903 |
|
|
2017
Q3 | – | Sell |
-40
| Closed | -$20K | – | 7939 |
|
|
2017
Q2 | $20K | Buy |
+40
| New | +$17.5K | ﹤0.01% | 6303 |
|
|
2016
Q1 | – | Sell |
-200
| Closed | -$109K | – | 8065 |
|
|
2015
Q4 | $109K | Hold |
200
| – | – | ﹤0.01% | 5141 |
|
|
2015
Q3 | $93K | Hold |
200
| – | – | ﹤0.01% | 5291 |
|
|
2015
Q2 | $102K | Sell |
200
-700
| -78% | -$342K | ﹤0.01% | 5390 |
|
|
2015
Q1 | $406K | Sell |
900
-3,800
| -81% | -$1.61M | ﹤0.01% | 4311 |
|
|
2014
Q4 | $1.93M | Buy |
+4,700
| New | +$1.85M | ﹤0.01% | 2944 |
|
Other funds holding REGN
VCM
N
UBS Group's REGN Position: Q1 2026 in Review
UBS Group increased its Regeneron Pharmaceuticals (REGN) stake by 11% in Q1 2026, buying an estimated $22.1M and bringing the position to 299,979 shares worth $232M. The position accounts for 0.03% of the portfolio, ranked #548.
UBS Group first reported a position in REGN in Q4 2014 and has held it in 46 quarters since. The position peaked at $286M in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- UBS Group held 299,979 shares of Regeneron Pharmaceuticals worth $232M as of Q1 2026.
- UBS Group bought 28,821 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $22.1M.
- Regeneron Pharmaceuticals made up 0.03% of UBS Group's portfolio in Q1 2026, its #548 holding.
- UBS Group first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Regeneron Pharmaceuticals position peaked at $286M in Q3 2024.
- 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.